OakChart

Elicio Therapeutics Inc

ELTXHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

1.63+0.02 (1.24%)
2026-11-12 02:03 CET
Market cap
45.57 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-35.74 USD m
Free cash flow, TTM
-36.99 USD m
EPS diluted, TTM
-1.81
P/E
-
Compare

Price

ELTX against its 20, 50 and 200-day averages
2050200beatmiss
5.0010.0015.0025.6M51.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ELTXclose 1.6320-day 1.6650-day 1.85200-day 6.521.6352w high

89.8% under the 52-week high of 16.00 on 10 Jun 2026. 52-week low 1.25 on 6 Nov 2026. Last 15 sessions, 58.4% high to low

Volume 1.13× normal · the line is the 50-bar volume average

Profile

ELTX
52-week range, 3% of the way up
1.2516.00

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. It focuses on its Amphiphile platform for trafficking lymph nodes. The company was founded by Darrell Irvine in August 2011 and is headquartered in Boston, MA.

IndexRUT
Employees33
IPOFeb 05, 2021
Beta1.63
ATR, 14d0.19
Rel volume1.13
Short float9.00%
Insider own27.95%
Inst own20.68%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap46.14M
Enterprise Value29.23M
Income-35.74M
Sales0.00M
Book/sh0.67
Cash/sh1.09
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees33
IPOFeb 05, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.45
P/C1.49
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio3.43
Current Ratio3.43
Debt/Eq0.74
LT Debt/Eq0.55
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.81
EPS next Y-1.42
EPS next Q-0.38
EPS this Y34.98%
EPS next Y15.59%
EPS next 5Y9.44%
EPS past 3/5Y85.75% 37.53%
Sales past 3/5Y- -
EPS Y/Y TTM46.62%
Sales Y/Y TTM-
EPS Q/Q49.75%
Sales Q/Q-
EarningsNov 05 AMC
EPS/Sales Surpr.37.47% -

Ownership

Insider Own27.95%
Insider Trans0.00%
Inst Own20.68%
Inst Trans15.09%
ROA-105.29%
ROE-315.32%
ROIC-122.14%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-1.94%
SMA50-11.82%
SMA200-75.00%
Trades-

Technical

Shs Outstand28.31M
Shs Float20.40M
Short Float9.00%
Short Ratio5.81
Short Interest1.84M
52W High16.00 -89.81%
52W Low1.25 30.40%
Volatility15.71% 13.09%
ATR (14)0.19
RSI (14)45.27
Beta1.63
Rel Volume1.13
Avg Volume315.90K
Volume357,227

Performance

Perf Week4.49%
Perf Month-7.91%
Perf Quarter-48.25%
Perf Half Y-85.58%
Perf YTD-79.52%
Perf Year-82.34%
Perf 3Y-72.23%
Perf 5Y-96.35%
Perf 10Y-
Recom1.40
Target Price14.12
Prev Close1.61
Price1.63
Change %1.24%

Analyst ratings

latest 4 of 4
DateActionAnalystRating changeTargetImplied
Jun 18, 2026ResumedLLadenburg ThalmannBuy$12+636.2%
Jun 10, 2026InitiatedRB. Riley SecuritiesBuy$27+1,556.4%
Apr 15, 2026InitiatedLLadenburg ThalmannBuy$20+1,127.0%
Mar 10, 2026InitiatedRRodman & RenshawBuy$17+942.9%

Peers

Mkt cap
TickerCompanyMkt cap
GLSIGreenwich LifeSciences Inc236.17M
IMMPImmutep Limited ADR26.24M
PDSBPDS Biotechnology Corp107.11M
EVAXEvaxion A/S ADR24.27M
GOVXGeovax Labs Inc1.10M
ANIXAnixa Biosciences Inc96.65M
HURATuHURA Biosciences Inc96.87M
CRDFCardiff Oncology Inc59.54M
IMRXImmuneering Corp245.45M
IMNNImunon Inc4.04M

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
DeMuth PeterChief Scientific OfficerDec 09 '25Option Exercise4.413621,596743Dec 10 05:05 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
RSSLGlobal X Russell 2000 ETFAUM: 1.43B
ITWOProShares Russell 2000 High Income ETFAUM: 178.20M
URTYProShares UltraPro Russell2000 3x SharesAUM: 277.82M

News

latest 14 of 200
  • Elicio Therapeutics: Q3 Earnings Snapshot (Associated Press) -10.26% +7.86%
  • Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC (GlobeNewswire)
  • Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting (GlobeNewswire) -5.41%
  • Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine (GlobeNewswire)
  • Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026 (GlobeNewswire)
  • Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference (GlobeNewswire)
  • Elicio Therapeutics: Q2 Earnings Snapshot (Associated Press)
  • Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
  • Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
  • Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering (GlobeNewswire) -15.02%
  • Another Blow For ELTX? Elicio Raises Fresh Capital Weeks After Trial Disappointment (Stocktwits) -37.35%
  • Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.300-0.480-0.3000.000.004
2026Q22026-08-13-0.430-0.538-0.4270.000.004
2026Q12026-05-11-0.650-0.465-0.6490.000.002
2025Q42026-03-12-0.450-0.445-0.4340.000.002
2025Q32025-11-13-0.600-0.480-0.6040.000.001
2025Q22025-08-07-0.660-0.685-0.6580.000.002
2025Q12025-05-13-0.870-0.830-0.8660.000.003
2024Q42025-03-31-1.070-0.875-1.2700.000.002
2024Q32024-11-13-1.390-0.730-1.3870.000.003
2024Q22024-08-13-0.640-0.960-0.6410.000.002
2024Q12024-05-15-1.150-1.090-1.1510.000.002
2023Q42024-03-29-1.250-1.030-0.9320.000.001
2023Q32023-11-09-1.270-0.800-1.2720.000.002
2023Q22023-08-11-2.610--2.4380.00--
2022Q42023-03-17-2.100-2.100-2.1390.000.001
2022Q32022-11-14-3.000-3.200-2.9850.630.632

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-54.300-53.425-27.1692.892.98
2021FY-19.300-28.100-19.32128.319.79
2023FY-6.960-2.530-6.9610.000.00
2024FY-4.250-4.065-4.2530.000.00
2025FY-2.580-2.505-2.5800.000.00
2026FY--1.678--0.00
2027FY--1.416--0.00
2028FY--1.916---
2029FY--1.300---
2030FY--1.300---

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-063000.000.000.00
2026Q4S2026-11-053000.000.000.00
2026Q4S2026-09-163000.000.000.00
2026Q4S2026-08-144000.000.000.00
2026Q4S2026-06-174000.000.000.00
2026Q4S2026-06-083000.000.000.00
2026Q4S2026-05-122000.000.000.00
2026Q4S2026-03-132000.000.000.00
2026Q4S2025-11-182000.000.000.00
2026Q4S2025-11-141000.000.000.00
2026Q4R2026-11-06110-0.42-0.42-0.42
2026Q4R2026-11-05100-0.55-0.55-0.55
2026Q4R2026-10-28100-0.55-0.55-0.55
2026Q4R2026-08-20101-0.55-0.55-0.55

Estimate history

EPS, annual5.02-8.481-13.79-27.169-19.321-892.664-6.961-4.253-2.584-1.8132
Period201220182019202020212022202320242025TTM
EPS, quarterly-1.387-1.27-0.866-0.658-0.604-0.434-0.649-0.427-0.304
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual7.2984.0291.4872.8828.31200000
Period201220182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.0612.9482.9482.9482.9960.0329.60411.02917.828.307
Period201220182019202020212022202320242025MRQ
Shares, quarterly10.78411.02915.96916.26317.25917.818.6421.90228.307
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.0028.312.881.494.03
Cost of Goods Sold Incl. D&A1.141.131.181.171.061.231.821.140.38
Gross Profit-1.14-1.13-1.18-1.17-1.0627.081.060.353.65
Selling, General and Administrative Excl. Other37.1836.5943.8134.5822.6866.3956.3438.9417.99
Research and Development23.3824.7033.3422.6817.0548.6138.8829.799.15
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-38.33-37.71-44.99-35.74-23.73-39.31-55.27-38.59-14.34
Interest Expense1.571.130.461.063.601.858.85--
Unusual Expense-3.471.927.39-1.030.9413.0716.532.566.08
Net Income Before Taxes-35.68-39.57-51.90-35.20-28.21-54.57-80.11-40.66-20.02
Income Taxes0.060.000.000.000.000.000.000.000.00
Consolidated Net Income-35.74-39.57-51.90-35.20-28.21-54.57-80.11-40.66-20.02
Net Income From Continuing Operations-35.74-39.57-51.90-35.20-28.21-54.57-80.11-40.66-20.02
Net Income-35.74-39.57-51.90-35.20-28.21-54.57-80.11-40.66-25.00
EPS (Recurring)-1.45-2.50-3.83-7.10-871.77-16.08-23.25-13.18-7.04
EPS (Basic, Before Extraordinaries)-1.81-2.58-4.25-6.96-892.66-19.32-27.17-13.79-8.48
EPS (Diluted)-1.81-2.58-4.25-6.96-892.66-19.32-27.17-13.79-8.48
EBITDA-37.18-36.59-43.81-34.58-22.68-38.51-54.65-38.09-14.34
Non-Operating Income (Expense)0.741.190.930.580.07-0.340.540.490.40
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.452.701.451.180.5812.044.723.342.98
Price To Sales Ratio----10.602.89---
Gross Margin-----95.6436.8823.6090.57
Operating Margin------138.84-1,919.20-2,595.23-355.97
Net Margin------192.76-2,781.49-2,734.23-620.63
Shares Outstanding28.3117.8011.039.600.033.002.952.952.95
Market Capitalization45.5745.5755.0470.1224.4486.8885.91--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.280.280.290.290.280.280.280.30
Gross Profit-0.28-0.28-0.29-0.29-0.28-0.28-0.28-0.30
Selling, General and Administrative Excl. Other8.1710.1510.318.567.769.8110.4613.17
Research and Development4.866.786.715.034.996.957.7210.62
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-8.45-10.43-10.60-8.84-8.04-10.09-10.74-13.48
Interest Expense0.410.410.410.340.430.190.180.23
Unusual Expense-0.71-2.480.98-1.261.810.860.510.61
Net Income Before Taxes-7.92-8.22-11.82-7.72-10.08-10.56-11.21-14.00
Income Taxes0.060.000.000.000.000.000.000.00
Consolidated Net Income-7.98-8.22-11.82-7.72-10.08-10.56-11.21-14.00
Net Income From Continuing Operations-7.98-8.22-11.82-7.72-10.08-10.56-11.21-14.00
Net Income-7.98-8.22-11.82-7.72-10.08-10.56-11.21-14.00
EPS (Recurring)-0.32-0.52-0.61-0.48-0.53-0.62-0.84-1.23
EPS (Basic, Before Extraordinaries)-0.30-0.43-0.65-0.43-0.60-0.66-0.87-1.27
EPS (Diluted)-0.30-0.43-0.65-0.43-0.60-0.66-0.87-1.27
EBITDA-8.17-10.15-10.31-8.56-7.76-9.81-10.46-13.17
Non-Operating Income (Expense)0.230.140.170.200.200.580.210.31
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.880.940.870.770.700.710.520.46
Shares Outstanding28.3121.9018.6417.8017.2616.2615.9711.03
Market Capitalization46.1474.63196.65139.22178.74123.5097.7155.04

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments18.5618.8013.627.8088.7634.615.5725.51
Short Term Receivables0.000.000.000.000.815.000.440.11
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets0.751.902.732.921.690.710.100.06
Total Current Assets19.3120.6916.3510.7291.2540.326.1125.68
Net Property, Plant & Equipment5.086.197.288.504.444.234.780.02
Total Investments and Advances0.700.700.690.620.720.821.000.93
Intangible Assets0.000.00---0.000.000.00
Other Assets0.770.602.832.830.111.980.000.00
Total Assets25.8628.1827.1522.6696.5147.3511.8926.63
Short Term Debt Incl. Current Port. of LT Debt1.010.900.910.690.9580.566.880.00
Accounts Payable0.671.044.372.814.715.5811.240.53
Other Current Liabilities6.439.584.493.375.6321.318.466.82
Total Current Liabilities8.1111.529.776.8711.30107.4526.577.36
Long Term Debt13.5025.146.016.793.714.483.900.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities2.622.830.000.090.0025.860.000.36
Total Liabilities24.2339.4915.7713.7515.01137.8030.477.72
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.00111.060.000.000.000.00
Common Equity1.64-11.3111.37-102.1481.51-90.45-18.5918.91
Total Shareholders Equity1.64-11.3111.378.9281.51-90.45-18.5918.91
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity1.64-11.3111.378.9281.51-90.45-18.5918.91
Total Liabilities & Stockholders Equity25.8628.1827.1522.6696.5147.3511.8926.63
Book Value Per Share0.09-1.031.18-3,189.2327.21-30.68-6.306.41
Tangible Book Value Per Share0.09-1.031.18-3,189.2327.21-30.68-6.306.41
Full-Time Employees33323237153--
Price to Book Ratio2.42-2.905.260.491.071.33--
Return on Assets-146.45-187.61-88.06-47.34-75.87-270.48-211.13-
Return on Equity--170,157.38-127.65-62.39---25,020.31-
Return on Invested Capital-261.42-375.34-202.50-179.62-64.04---105.89
Quick Ratio2.381.801.671.568.080.380.233.49
Current Ratio2.381.801.671.568.080.380.233.49

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-35.74-39.57-51.90-35.20-28.21-54.57-80.11-40.66-20.02
Depreciation1.141.131.181.171.060.800.630.500.00
Other Funds (Non Cash)0.134.949.691.395.1227.1030.825.828.91
Funds from Operations-34.47-33.51-41.03-32.64-22.03-26.67-48.66-34.34-11.11
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-2.50-3.443.96-0.06-0.15-25.9725.779.753.09
Cash from Operating Activities-36.97-36.95-37.07-32.69-22.18-52.64-22.89-24.59-8.02
Capital Expenditures-0.02-0.02-0.09-0.07-0.65-0.38-0.04-0.240.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.030.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.02-0.02-0.08-0.03-0.65-0.38-0.04-0.240.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock47.1926.8322.596.9821.20109.3320.29-0.3828.60
Repurchase of Common Pref Stock0.000.00-0.55-0.150.000.00-0.04-0.380.00
Sale of Common Pref Stock47.1926.8323.147.1321.20109.3320.330.0028.60
Proceedsfrom Stock Options47.7916.245.637.0021.12107.4919.520.0028.59
Issuance or Reduction of Debt, Net0.009.8719.7310.000.000.2932.125.263.15
Change in Long Term Debt0.009.8719.7310.000.000.2932.125.263.15
Issuance of Long Term Debt0.009.8719.7310.000.000.3032.125.263.15
Reduction of Long Term Debt0.000.000.000.000.00-0.010.000.000.00
Net Financing Active Other Cash Flow0.000.000.0021.640.00-2.450.000.000.00
Other Financing Activities Uses0.000.000.00-2.360.00-2.470.000.000.00
Cash from Financing Activities47.1936.7042.3238.6121.20107.1752.414.8931.74
Exchange Rate Effect-0.100.050.02-0.180.00-0.44--
Net Change in Cash10.10-0.235.195.89-1.6354.1529.04-19.9423.72
Free Cash Flow-36.99-36.97-37.16-32.76-22.83-53.02-22.93-24.83-8.02
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments30.9023.4814.9518.5620.6122.09
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets3.132.001.250.750.850.51
Total Current Assets34.0325.4816.2019.3121.4622.60
Net Property, Plant & Equipment4.224.504.795.085.355.63
Total Investments and Advances0.520.520.710.700.700.70
Intangible Assets0.000.000.000.000.000.00
Other Assets0.820.820.990.770.770.60
Total Assets39.6031.3322.6925.8628.2829.53
Short Term Debt Incl. Current Port. of LT Debt3.581.071.041.010.980.95
Accounts Payable0.380.840.270.670.323.87
Other Current Liabilities5.977.295.926.435.215.11
Total Current Liabilities9.939.207.238.116.519.92
Long Term Debt10.4113.0713.3013.5014.0813.95
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.411.123.602.623.883.82
Total Liabilities20.7523.3924.1324.2324.4727.69
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity18.857.94-1.441.643.821.83
Total Shareholders Equity18.857.94-1.441.643.821.83
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity18.857.94-1.441.643.821.83
Total Liabilities & Stockholders Equity39.6031.3322.6925.8628.2829.53
Book Value Per Share0.670.36-0.080.090.220.11
Tangible Book Value Per Share0.670.36-0.080.090.220.11
Full-Time Employees---33--
Price to Book Ratio2.45-50.72116.3136.0097.0113.85
Return on Assets-105.29-124.36-158.11-146.45-137.56-241.23
Return on Equity-315.32-774.56-1,076.34---60,013.19
Return on Invested Capital-27.27-39.11-99.68-50.99-56.35-66.91
Quick Ratio3.432.772.242.383.292.28
Current Ratio3.432.772.242.383.292.28

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-7.98-8.22-11.82-7.72-10.08-10.56
Depreciation0.280.280.290.290.280.28
Other Funds (Non Cash)0.50-1.491.92-0.802.891.68
Funds from Operations-7.19-9.42-9.61-8.24-6.91-8.60
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-3.171.26-2.031.44-4.18-0.35
Cash from Operating Activities-10.36-8.16-11.64-6.80-11.09-8.95
Capital Expenditures0.000.000.00-0.020.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.00-0.020.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock17.7916.518.034.86-0.2911.93
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock17.7916.518.034.86-0.2911.93
Proceedsfrom Stock Options17.7916.497.935.58-1.332.02
Issuance or Reduction of Debt, Net0.000.000.000.009.870.00
Change in Long Term Debt0.000.000.000.009.870.00
Issuance of Long Term Debt0.000.000.000.009.870.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities17.7916.518.034.869.5711.93
Exchange Rate Effect-0.00-0.000.01-0.100.040.07
Net Change in Cash7.428.34-3.61-2.05-1.483.06
Free Cash Flow-10.36-8.16-11.64-6.81-11.09-8.95

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.00%1.8M20.4M311.55K
2026-10-158.72%1.7M19.5M316.40K
2026-09-308.20%1.6M18.9M550.15K
2026-09-158.80%1.7M18.9M1.62M
2026-08-318.77%1.6M18.1M1.69M
2026-08-149.31%1.7M18.1M1.68M
2026-07-3112.10%1.7M14.4M1.67M
2026-07-1512.99%1.9M14.4M1.65M
2026-06-3013.18%1.7M13.2M1.37M
2026-06-1514.84%2.0M13.2M261.51K
2026-05-2914.67%1.9M12.9M137.09K
2026-05-1513.64%1.7M12.8M135.05K
2026-04-3013.27%1.7M12.5M142.95K
2026-04-1511.73%1.4M12.3M136.51K
2026-03-3110.95%1.3M12.0M133.34K
2026-03-1310.75%1.3M12.0M129.73K
2026-02-2711.43%1.3M11.4M115.62K
2026-02-1311.24%1.3M11.4M114.99K
2026-01-3010.52%1.2M11.4M101.42K
2026-01-1510.05%1.2M11.5M101.34K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.750.053.1161,0710.000.262-0.0150.001
call5.000.001.500.045.4653890.000.186-0.0210.001
call7.500.000.050.155.45215.000.000.101-0.0130.000
call10.000.001.100.016.1291270.000.094-0.0140.000
call12.500.000.100.136.6324250.000.090-0.0140.000
call15.000.001.850.057.36133.000.000.086-0.0170.000
call17.500.004.900.107.61520.000.000.084-0.0170.000
call20.000.005.000.058.0021300.000.082-0.0170.000
call22.500.005.000.208.25713.000.000.081-0.0180.000
call25.000.004.900.008.3770.000.000.080-0.0170.000
put2.500.001.250.906.0521,7830.00-0.738-0.0140.001
put5.002.506.002.700.00026.000.00-0.814-0.0200.001
put7.503.507.304.5524.32113.000.00-0.899-0.0140.000
put10.006.0010.808.120.0001.000.00-0.906-0.0140.000
put12.5010.2013.1010.600.0002.000.00-0.911-0.0150.000
put15.0011.3015.809.000.00075.000.00-0.914-0.0150.000
put17.5013.5018.200.000.0000.000.00-0.916-0.0150.000
put20.0016.0020.800.000.0000.000.00-0.918-0.0150.000
put22.5018.5023.000.000.0000.000.00-0.919-0.0150.000
put25.0021.0025.800.000.0000.000.00-0.921-0.0150.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-09DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342025-12-31SEC
2026-09-148-KCurrent report2026-09-14SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-16SCHEDULE 13GSEC
2026-07-08SCHEDULE 13G/ASEC
2026-07-02424B5SEC
2026-07-028-KCurrent report2026-07-01SEC
2026-06-248-KCurrent report2026-06-24SEC
2026-06-178-KCurrent report2026-06-17SEC
2026-06-158-KCurrent report2026-06-15SEC
2026-05-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-118-KCurrent report2026-05-11SEC
2026-04-2910-K/A2025-12-31SEC
2026-03-16EFFECTEffectiveness filing by commission orderSEC
2026-03-16424B5SEC
2026-03-168-KCurrent report2026-03-16SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Knoll Capital Management, LLC6.35%
SHAH CAPITAL MANAGEMENT4.76%
BlackRock, Inc.4.01%
VANGUARD CAPITAL MANAGEMENT LLC3.00%
GEODE CAPITAL MANAGEMENT, LLC1.58%
STATE STREET CORP0.94%
UBS Group AG0.90%
NORTHERN TRUST CORP0.68%
Ikarian Capital, LLC0.52%
VANGUARD PORTFOLIO MANAGEMENT LLC0.47%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.18%
iShares Russell 2000 ETF1.67%
VANGUARD EXTENDED MARKET INDEX FUND0.75%
iShares Russell 2000 Growth ETF0.64%
Fidelity Small Cap Index Fund0.60%
Fidelity Extended Market Index Fund0.30%
VANGUARD RUSSELL 2000 INDEX FUND0.29%
iShares Micro-Cap ETF0.23%
EQ/AB Small Cap Growth Portfolio0.21%
EQ/Small Company Index Portfolio0.21%

OakChart. ELTX. Cached 15 minutes.